Juan Jose Marugan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Juan Jose Marugan has a total of 609 co-authors. Here are the top co-authors by number of shared publications:
- Mark J. Henderson
Division of Preclinical Innovation, National Center for Advancing Translational Sciences, National Institutes of Health
40 shared publications - Noel Southall
National Center for Advancing Translational Sciences, National Institutes of Health, Bethesda, MD, USA
34 shared publications - Xin Xu
National Center for Advancing Translational Sciences (NCATS), Rockville, USA
34 shared publications - Raul Calvo
National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, Maryland
33 shared publications - Udo Rudloff
Rare Tumor Initiative, Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA
27 shared publications - Dingyin Tao
National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, USA
25 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from The Brain-Penetrant Pan-ErbB Inhibitor Poziotinib Effectively Targets HER2+ Breast Cancer Brain Metastases
Effect of ErbB inhibitors on cell viability in BCBM94 and HME-1 cells
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from The Brain-Penetrant Pan-ErbB Inhibitor Poziotinib Effectively Targets HER2+ Breast Cancer Brain Metastases
Effect of ErbB inhibitors on cell viability in BCBM94 and HME-1 cells
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Suppl Fig 5 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity
Suppl Fig 5 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig 5 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity
Suppl Fig 5 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from The Brain-Penetrant Pan-ErbB Inhibitor Poziotinib Effectively Targets HER2+ Breast Cancer Brain Metastases
ErbB inhibitor response in the presence of rhNRG1
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from The Brain-Penetrant Pan-ErbB Inhibitor Poziotinib Effectively Targets HER2+ Breast Cancer Brain Metastases
ErbB inhibitor response in the presence of rhNRG1
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Suppl Fig 2 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity
Suppl Fig 2 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSuppl Fig 2 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity
Suppl Fig 2 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S3 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity
Supplementary Data_Drug Curves
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S3 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity
Supplementary Data_Drug Curves
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity
Cytotoxicity study of peptide analogs
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Fatty Acid Derivatization and Cyclization of the Immunomodulatory Peptide RP-182 Targeting CD206high Macrophages Improve Antitumor Activity
Cytotoxicity study of peptide analogs
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from The Brain-Penetrant Pan-ErbB Inhibitor Poziotinib Effectively Targets HER2+ Breast Cancer Brain Metastases
Supplemental figures and legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from The Brain-Penetrant Pan-ErbB Inhibitor Poziotinib Effectively Targets HER2+ Breast Cancer Brain Metastases
Supplemental figures and legends